"Nizatidine" from_date:2012

Efficacy and safety of rebamipide/nizatidine in patients with erosive gastritis: A randomized, multicenter, phase 4 study. For the treatment of gastritis, rebamipide, a mucoprotective agent, and nizatidine, a gastric acid suppressant, are commonly employed individually. To compare the efficacy of Mucotra SR (rebamipide 150 mg) and Axid (nizatidine 150 mg) combination therapy with the sole administration of Axid in managing erosive gastritis. A total of 260 patients diagnosed with endoscopically confirmed erosive gastritis were enrolled in this open-label, multicenter, randomized, phase 4 clinical trial, allocating them into two groups: Rebamipide/nizatidine combination twice daily nizatidine twice daily for 2 weeks. The full-analysis set analysis encompassed 239 patients (rebamipide/nizatidine

Nizatidine An official website of the United States government Here's how you know Log inAccess keysNCBI HomepageMyNCBI HomepageMain ContentMain NavigationBookshelfSearch databaseBooksAll DatabasesAssemblyBiocollectionsBioProjectBioSampleBooksClinVarConserved DomainsdbGaPdbVarGeneGenomeGEO DataSetsGEO ProfilesGTRHomoloGeneIdentical Protein GroupsMedGenMeSHNLM and EffectsSummary of Use during LactationBecause of the low levels of nizatidine in breastmilk, amounts ingested by the infant are small and would not be expected to cause any adverse effects in breastfed infants. No special precautions are required. Histamine H2-antagonists with more extensive use might be preferred in newborns.Drug LevelsMaternal Levels. Three women who had been breastfeeding for 3 to 8 months

Formulation, optimization, and evaluation of raft-forming formulations containing Nizatidine. The main objective of this research is to formulate, optimize, and evaluate raft-forming chewable tablets of Nizatidine. Various raft-forming agents were used in preliminary screening. Sodium alginate showed maximum raft strength, so tablets were prepared using sodium alginate as the raft forming agent , along with calcium carbonate (CaCO) as antacid and raft strengthening agent, and sodium bicarbonate (NaHCO) as a gas generating agent. Raft forming chewable tablets containing Nizatidine were prepared by direct compression and wet granulation methods, and evaluated for drug content, acid neutralization capacity, raft strength, and in-vitro drug release in 0.1 N HCl. Box-Behnken design was used

The Effect of Nizatidine, a MATE2K Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Metformin in Healthy Volunteers. In the proximal tubule, basic drugs are transported from the renal cells to the tubule lumen through the concerted action of the H(+)/organic cation antiporters, multidrug and toxin extrusion (MATE) 1 and MATE2K. Dual inhibitors of the MATE transporters have on the pharmacokinetics and pharmacodynamics of metformin in healthy subjects. Strategic cell-based screening of 71 US Food and Drug Administration (FDA)-approved medications was conducted to identify selective inhibitors of renal organic cation transporters that are capable of inhibiting at clinically relevant concentrations. From this screen, nizatidine was identified and predicted to be a clinically potent

Phase IV Clinical Trial to Compare the Efficacy and Safety of Rebamipide/Nizatidine Combination Therapy With Nizatidine Monotherapy in Patients With Gastritis The purpose of this study is to compare the Efficacy and Safety of Rebamipide/Nizatidine Combination Therapy with Nizatidine Monotherapy in Patients with Gastritis The purpose of this study is to compare the Efficacy and Safety of Rebamipide/Nizatidine Combination Therapy with Nizatidine Monotherapy in Patients with Gastritis.Anticipated result is to prove superiority of Rebamipide/Nizatidine combination therapy at 2 weeks compared to Nizatidine Monotherapy.

Impact of sleep disorders in Japanese patients with functional dyspepsia (FD): Nizatidine improves clinical symptoms, gastric emptying and sleep disorders in FD patients. The association between functional dyspepsia (FD) and sleep disorders has yet to be studied in detail. The aim of this study is to evaluate the risk factors associated with sleep disorders and the clinical response to nizatidine therapy for sleep disorders in Rome III-based FD patients. We enrolled 94 FD patients and 52 healthy volunteers. We used Rome III criteria to evaluate upper abdominal symptoms, and the Self-Rating Questionnaire for Depression scores to determine depression status. Sleep disorder was evaluated using Pittsburgh Sleep Quality Index (PSQI) scores, and degree of anxiety by the State-Trait Anxiety

'. Metformin may be effective in preventing weight gain (MD -4.03 kg, 95% CI -5.78 to -2.28; 4 studies, 131 participants; low-certainty evidence); and BMI increase (MD -1.63 kg/m2, 95% CI -2.96 to -0.29; 5 studies, 227 participants; low-certainty evidence). Other agents that may be slightly effective in preventing weight gain include H2 antagonists such as nizatidine, famotidine and ranitidine (MD -1.32 kg

generation agents preferred) * H2 histamine receptor antagonists (e.g. nizatidine, famotidine) * Anti-leukotriene medications (e.g. Montelukast) * Mast cell stabilisers (e.g. sodium cromoglicate, ketotifen) * There are no evidence-based dietary modifications recommended for patients with MCAS.18 Current consensus guidelines do not suggest any dietary modifications for MCAS. It is not uncommon for patients

. While serum magnesium levels typically rise quickly with therapy, replenishing intracellular stores takes longer. Medication induced hypomagnesaemiaIf hypomagnesaemia is believed to be induced by medication, consider alternative treatments. Proton Pump InhibitorsConsider histamine 2 receptor antagonists, like famotidine or nizatidine, for patients who need an alternative to proton pump inhibitors

Prescription patterns of ranitidine in Canada DSEN Abstract: Prescription patterns of ranitidine, nizatidine, famotidine, and cimetidine in Canada - CIHR * Skip to main content * Skip to "About this site" * Canada.ca * Services * Departments * Language selection * * Français * Search and menus * Search and menusCanadian Institutes of Health Research SearchSearch website Search Topics menu * Funding * Institutes * College of Reviewers * Initiatives * Collaboration * Discoveries for lifeYou are here: 1. 2. Home 3. Initiatives 4. Drug Safety and Effectiveness Network 5. DSEN AbstractPrescription patterns of ranitidine, nizatidine, famotidine, and cimetidine in CanadaOther formatPDF version (157 KB)What is the issue?Histamine H-2 (H2) blockers, including ranitidine

and simeticone are also considered acceptable for use during breastfeeding.Histamine (H2)-receptor antagonistsAny H2-receptor antagonist can be used during breastfeeding. Famotidine or nizatidine are preferred as smaller amounts pass into breast milk. Cimetidine is least preferred due to higher levels in breast milk and the potential for drug interactions.Proton pump inhibitors (PPIs)Any PPI can be used during

. Bertaccini G, Scarpignato C (1982) Histamine H2-antagonists modify gastric emptying in the rat. Br J Pharmacol. 77(3):443–448 CAS PubMed PubMed Central Google Scholar 59. Ueki S, Seiki M, Yoneta T, Aita H, Chaki K, Hori Y, Morita H, Tagashira E, Itoh Z (1993) Gastroprokinetic activity of nizatidine, a new H2-receptor antagonist, and its possible mechanism of action in dogs and rats. J

H2 receptor antagonists You need to be logged in to see the full monograph.LoginUSE OF H2 RECEPTOR ANTAGONISTS IN PREGNANCYDate of issue: February 2024, Version: 4A corresponding patient information leaflet on USE OF H2 RECEPTOR ANTAGONISTS IN PREGNANCY is available.Histamine H2-receptor antagonists (H2RAs) (cimetidine, famotidine, nizatidine and ranitidine) reduce gastric acidity through

biological agents (9 studies), disease‐modifying antirheumatic drugs (5 studies) and dehydroepiandrosterone (2 studies). There was one study on gamma‐linolenic acid, nizatidine, omega‐3 supplements and traditional Chinese medicine * 17 studies were considered to be at low risk of bias. * 14 studies contributed to a meta-analysis with two comparison being sufficiently clinically homogenous to perform on Google+Mark as readShare this post: Share on FacebookTweet this on TwitterShare on LinkedInShare on Google+Share via emailCreate a personal elf note about this blogTagged with: cevimeline, dehydroepiandrosterone, dry mouth, gamma-linolenic acid, interferon, nizatidine, oral medicine and pathology, pilocarpine, rituximab, saliva stimulants, saliva subsitutes, salivary flow rate, Sjögren's syndromeDerek